Grant ID RP230444
Awarded On August 16, 2023
Title A Role for PSMD2, PSMD7, and PSMD9 in Drug Resistance of Acute Myeloid Leukemia (AML)
Program Academic Research
Award Mechanism TREC: Pilot Study Award
Institution/Organization Texas Tech University Health Sciences Center at El Paso
Principal Investigator/Program Director Anna Eiring
Cancer Sites Bone
Contracted Amount $200,000
Lay Summary

Acute myeloid leukemia (AML) is a highly aggressive form of cancer arising from the presence of abnormal white blood cells in the bone marrow. While many AML patients initially respond well to therapy, the 5-year survival rate is poor (less than 25%), due to drug resistance and disease recurrence. Bortezomib, an inhibitor that blocks protein degradation, has shown promising results in the treatment of some AML patients. However, resistance is a clinical problem, and treatment is often associated with significant side effects and eventually drug resistance. The proteasome is an intracellular structure responsible for protein degradation. Standard proteasome inhibitors like bortezomib target ...

Read More